NO20093542L - Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer - Google Patents

Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer

Info

Publication number
NO20093542L
NO20093542L NO20093542A NO20093542A NO20093542L NO 20093542 L NO20093542 L NO 20093542L NO 20093542 A NO20093542 A NO 20093542A NO 20093542 A NO20093542 A NO 20093542A NO 20093542 L NO20093542 L NO 20093542L
Authority
NO
Norway
Prior art keywords
antibodies
tumor metastasis
neuropilin
inhibition
nrp2
Prior art date
Application number
NO20093542A
Other languages
English (en)
Inventor
Wei-Ching Liang
Yan Wu
Anil Durgadas Bagn
Ryan Jefferson Watts
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20093542L publication Critical patent/NO20093542L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Søknaden tilveiebringer Nrp2-antagonister, slik som anti-Nrp2-antistoffer, og deres anvendelse i forebyggelisen og behandlingen av tumormetastase.
NO20093542A 2007-05-17 2009-12-16 Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer NO20093542L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/069179 WO2008143665A1 (en) 2007-05-17 2007-05-17 Inhibition of tumor metastasis by anti neuropilin 2 antibodies

Publications (1)

Publication Number Publication Date
NO20093542L true NO20093542L (no) 2010-02-12

Family

ID=39301228

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093542A NO20093542L (no) 2007-05-17 2009-12-16 Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer

Country Status (17)

Country Link
US (2) US8648173B2 (no)
EP (1) EP2152307B1 (no)
JP (1) JP5745840B2 (no)
KR (1) KR101520115B1 (no)
CN (1) CN101754771B (no)
AU (1) AU2007353778B9 (no)
BR (1) BRPI0721660A2 (no)
CA (1) CA2687247A1 (no)
CR (1) CR11126A (no)
ES (1) ES2469743T3 (no)
HK (2) HK1134040A1 (no)
IL (1) IL202005A (no)
MA (1) MA31435B1 (no)
MX (1) MX2009012421A (no)
NO (1) NO20093542L (no)
UA (1) UA99292C2 (no)
WO (1) WO2008143665A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008251381B2 (en) * 2007-05-11 2014-10-30 The Johns Hopkins University Biomarkers for melanoma
JP2013507641A (ja) * 2009-10-13 2013-03-04 ザ・ジョンズ・ホプキンス・ユニバーシティー 黒色腫腫瘍細胞の識別のためのバイオマーカー
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
US10174385B2 (en) * 2013-12-20 2019-01-08 Trustees Of Boston University Assays and methods relating to the treatment of melanoma
WO2018195338A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
JP2020522562A (ja) * 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
AU2019247511A1 (en) * 2018-04-06 2020-10-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
JP2022551603A (ja) 2019-10-03 2022-12-12 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
CN114277152A (zh) * 2022-01-14 2022-04-05 张赟建 用于预测甲状腺***状癌***转移的特异性基因及制备方法
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
PT1787999E (pt) 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
CA2313348A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
EP1037925A2 (en) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Antagonists of neuropilin receptor functional and use thereof
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
EP1663293A2 (en) * 2003-09-23 2006-06-07 Ludwig Institute For Cancer Research Vege-cor vege-d materials and methods for stimulation of neural stem cells
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)

Also Published As

Publication number Publication date
IL202005A (en) 2014-11-30
KR101520115B1 (ko) 2015-05-13
US8920805B2 (en) 2014-12-30
IL202005A0 (en) 2010-06-16
HK1144556A1 (en) 2011-02-25
UA99292C2 (uk) 2012-08-10
MX2009012421A (es) 2009-12-01
MA31435B1 (fr) 2010-06-01
AU2007353778B2 (en) 2013-11-07
CN101754771A (zh) 2010-06-23
BRPI0721660A2 (pt) 2013-01-22
US20100172921A1 (en) 2010-07-08
WO2008143665A1 (en) 2008-11-27
CA2687247A1 (en) 2008-11-27
EP2152307B1 (en) 2014-04-16
AU2007353778B9 (en) 2014-04-03
HK1134040A1 (en) 2010-04-16
KR20100018567A (ko) 2010-02-17
CR11126A (es) 2010-05-19
ES2469743T3 (es) 2014-06-18
CN101754771B (zh) 2015-03-04
US20140234312A1 (en) 2014-08-21
AU2007353778A1 (en) 2008-11-27
US8648173B2 (en) 2014-02-11
EP2152307A1 (en) 2010-02-17
JP5745840B2 (ja) 2015-07-08
JP2010527350A (ja) 2010-08-12

Similar Documents

Publication Publication Date Title
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
NO20081636L (no) FAP - inhibitorer
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
RS52784B (en) They're TANATE RAZAGILINA
MX2010003013A (es) Inhibicion de angiogenesis.
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
TNSN08400A1 (en) Organic compounds and their uses
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application